Marcelo C Pasquini, Paul K Wallace, Brent Logan, Manmeet Kaur, Joseph D Tario, Alan Howard, Yali Zhang, Claudio Brunstein, Yvonne Efebera, Nancy Geller, Sergio Giralt, Parameswaran Hari, Mary M Horowitz, John Koreth, Amrita Krishnan, Heather Landau, George Somlo, Nina Shah, Edward Stadtmauer, Dan T Vogl, David H Vesole, Philip L McCarthy, Theresa Hahn
PURPOSE: Prognostic Immunophenotyping in Myeloma Response (PRIMeR) is an ancillary study of minimal residual disease (MRD) assessment for multiple myeloma by next-generation multiparameter flow cytometry (MFC). Patients were enrolled on a three-arm randomized control trial (Blood and Marrow Transplants Clinical Trials Network 0702 Stem Cell Transplant for Myeloma in Combination of Novel Agents [STaMINA]; ClinicalTrials.gov identifier: NCT01109004). METHODS: Four hundred and thirty-five patients consented to the MRD panel, which included 10 monoclonal antibodies measured via six-color MFC...
May 3, 2024: Journal of Clinical Oncology